Literature DB >> 15474052

Sequence and structural analysis of kinase ATP pocket residues.

Anna Vulpetti1, Roberta Bosotti.   

Abstract

Protein kinases represent one of the largest known families of enzymes. Most kinases bind ATP and most synthetic kinase inhibitors are ATP-competitive, which makes selectivity a potential problem. However, despite the high sequence similarity in the ATP binding pocket, several groups including ours have been able to develop highly potent and selective ATP-competitive inhibitors. To systematically aid the design of specific inhibitors in our protein kinase projects, we aligned all known three-dimensional structures and all known sequences of human protein kinases. We identified a set of 38 residues that make up the ATP pocket and analyzed the variability among these residues. The most variable residues in the ATP pocket are targeted to design specificity into inhibitors in our various kinase projects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474052     DOI: 10.1016/j.farmac.2004.05.010

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  23 in total

1.  Integrating molecular diagnostics into anticancer drug discovery.

Authors:  István Peták; Richárd Schwab; László Orfi; László Kopper; György Kéri
Journal:  Nat Rev Drug Discov       Date:  2010-06-07       Impact factor: 84.694

2.  Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity.

Authors:  Jinan Wang; Fangfang Wang; Zhengtao Xiao; Guowen Sheng; Yan Li; Yonghua Wang
Journal:  J Mol Model       Date:  2011-12-03       Impact factor: 1.810

Review 3.  The unusual mechanism of inhibition of the p90 ribosomal S6 kinase (RSK) by flavonol rhamnosides.

Authors:  Darkhan Utepbergenov; Zygmunt S Derewenda
Journal:  Biochim Biophys Acta       Date:  2013-03-27

4.  Phosphorylation and ATP-binding induced conformational changes in the PrkC, Ser/Thr kinase from B. subtilis.

Authors:  Paweł Gruszczyński; Michał Obuchowski; Rajmund Kaźmierkiewicz
Journal:  J Comput Aided Mol Des       Date:  2010-06-19       Impact factor: 3.686

Review 5.  Targeting ERK beyond the boundaries of the kinase active site in melanoma.

Authors:  Rachel M Sammons; Ranajeet Ghose; Kenneth Y Tsai; Kevin N Dalby
Journal:  Mol Carcinog       Date:  2019-06-12       Impact factor: 4.784

6.  The performance of ensemble-based free energy protocols in computing binding affinities to ROS1 kinase.

Authors:  Shunzhou Wan; Agastya P Bhati; David W Wright; Alexander D Wade; Gary Tresadern; Herman van Vlijmen; Peter V Coveney
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

7.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

8.  Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.

Authors:  Philip Chamberlain; Silvia Delker; Barbra Pagarigan; Afshin Mahmoudi; Pilgrim Jackson; Mahan Abbasian; Jeff Muir; Neil Raheja; Brian Cathers
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

9.  The rational design of specific peptide inhibitor against p38α MAPK at allosteric-site: a therapeutic modality for HNSCC.

Authors:  Kamaldeep Gill; Lokesh Nigam; Ratnakar Singh; Suresh Kumar; Naidu Subbarao; Shyam Singh Chauhan; Sharmistha Dey
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

10.  Prediction of specificity-determining residues for small-molecule kinase inhibitors.

Authors:  Daniel R Caffrey; Elizabeth A Lunney; Deborah J Moshinsky
Journal:  BMC Bioinformatics       Date:  2008-11-25       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.